Zepatier + Ribavirin + Sofosbuvir
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, Hepatitis C
Trial Timeline
Jul 20, 2016 → Jan 1, 2018
NCT ID
NCT02781649About Zepatier + Ribavirin + Sofosbuvir
Zepatier + Ribavirin + Sofosbuvir is a approved stage product being developed by Merck for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02781649. Target conditions include End-Stage Renal Disease, Hepatitis C.
What happened to similar drugs?
7 of 8 similar drugs in End-Stage Renal Disease were approved
Approved (7) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02781649 | Approved | Completed |
Competing Products
20 competing products in End-Stage Renal Disease